A Phase 1 interventional study of Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC) in Quorum Sensing, Prebiotics and Probiotics, sponsored by University of Nottingham. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-01.
Sponsored by University of Nottingham · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Sepsis with a site in United Kingdom — 14 open to participants now, 14 under way, 1 of them phase 3. Sepsis · United Kingdom.
Among the 95 studies in Sepsis with a site in United Kingdom, this one is the 38th largest by planned enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2009, is one of 2 in phase 1, and was the 14th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →14 of the 95 studies in Sepsis with a site in United Kingdom are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United Kingdom, United States, Argentina and 11 more countries
Ages 18–80
Liverpool University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Surrey County Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18+
NHS Greater Glasgow and Clyde · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 75 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 18 · Phase 4 4
First in 2002; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 215 across the 45 interventional studies, 180 across the 49 observational. Of the 58 that completed or were terminated, 12 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
University of Nottingham has 2 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
5 of the studies in Sepsis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179499Phase 3NHS Greater Glasgow and ClydeEarly Vasopressors in Sepsis | 2026-11 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
| NCT05647096Santersus AGSafety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis | 2027-05-05 |
| NCT06977165University of ManchesterInvestigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis | 2027-06-30 |
| NCT07131969University of CambridgeTranscriptional Analysis of Mechanisms in Liver Failure and Sepsis | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 95 studies in Sepsis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
It has recently been discovered that bacteria are able to communicate using specialised molecules known as Quorum Sensing Signalling Molecules (QSSMs). An accumulation of QSSMs in their surrounding environment allow for the bacteria to quantify the size of colonies. At specific colony sizes the concentration of QSSMs reaches a critical threshold leading to the activation of genes that cause an infection. It is by this mechanism that bacteria within a colony coordinate behaviour to activate infectivity when colony sizes are large enough to withstand defensive measures from the host's immune system. A disruption of quorum sensing may reduce the severity of infection and this has led to the development of inhibitors of quorum sensing as a new strategy in antibacterial therapy.
QSSMs are also thought to facilitate infection by other mechanisms and are able to influence the number and function of a specific type of immune cell known as an 'antigen presenting cell'. These cells are pivotal in allowing the immune system to recognise components of bacteria as foreign and thereby mount the appropriate response. It was found that large numbers of these types of cells underwent programmed cell death (cell suicide) in the presence of QSSMs compared to when QSSMs were absent. This mirrors the situation in blood sampled from patients with severe infections where there is a greater proportion of cell deaths among antigen presenting cells than other types of immune cell.
This study aims to establish in healthy volunteers, the mechanisms by which QSSMs affect immune cells and facilitate the spread of infection. Antibiotic administration in humans can alter the environment of the intestine and can lead to an overgrowth of harmful bacteria to potentially cause an infection. Probiotics supplements can prevent bacterial overgrowth and potentially reduce infective complications. The mechanism, which we aim to clarify, may involve changes in both the production of QSSMs and the function of immune cells.
Hypothesis
Aims
The aims of our study are 2 fold:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Bifidobacterium longum BB536 · Drug: Azithromycin
Dietary Supplement: Active hexose correlated compound (AHCC) · Drug: Azithromycin
Dietary Supplement: Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC) · Drug: Azithromycin
Dietary Supplement: Corn starch placebo capsule · Drug: Azithromycin
2 capsules od
One capsule tds
Drug page:
One capsule tds (prebiotic) and two capsules od (probiotic)
One capsule tds and two capsules od
250mg od
Serum QSSM level
Time frame: 14 days
T cell Th1/Th2 ratio
Time frame: 14 days
The record gives a start of Oct 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Active Hexose Correlated Compound